CHGA and neoplasm: Through this approach, we identified 12 key parameters—age, Ki-67, pancreas origin, lung origin, serum chromogranin A, CA19-9, CEA, AFP, CK7 immunohistochemical factor, oncological treatment, number of metastatic lymph nodes, and tumor size— and ultimately validated three of these parameters explicitly using both patient- and lesion-based statistical methods: tumor origin, adequacy of oncological treatment and the immunohistochemical marker CK7 (Figure 5).